Bio3 Research and Syngen Inc. (CA/USA)/Protelix Inc. (CA/USA)

Bio3 Research has entered into a strategic alliance with Syngen Inc. (CA/USA) and Protelix Inc. (CA/USA) for the development, under their technological platform, of SiRNA HMGB1 specific and Mimic Abs anti-HMGB1 in cardiovascular field (e.g. Restenosis and Atherosclerotic Plaque progression inhibition).

Bio3 Research and S.I.I.T.

Bio3 Research S.r.l. has entered in 2010 into a collaboration with the Italian company S.I.I.T from which it has obtained full rights to commercially exploit a proprietary oral formulation of Biocysan. The formulation is based on an innovative technology which allows the manufacturing of multi-layers tabs (2 layers). Each layer is characterized by a different Cysteine releasing time allowing the best absorption of the finished form during the haemodialysis session. Biocysan Free Sale Certificate as Neutraceutical in Italy is expected in July 2010.